Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Galapagos Pledges More Restraint On Pipeline Potential

But Keeping The Faith With Toledo

Executive Summary

The Belgium-headquartered firm has struggled of late to impress investors, most recently with data from its salt-inducible kinase inhibitors, and CMO Walid Abi-Saab told Scrip that one reason could be "the level of optimism that prevails in the company. We jump on things a bit ahead of time."

You may also be interested in...



Stoffels Sets Out Strategy To Save Galapagos

Pharma veteran Paul Stoffels, the new CEO of Galapagos, is not thinking about using the Belgian biotech’s cash pile to buy Phase III drugs but is open to licensing deals with US firms who have drugs approved at home and are looking for a European partner.

Bristol Lays Groundwork For First Dermatology Launch, Ahead Of TYK2 Inhibitor

The company has not even filed the TYK2 inhibitor deucravacitinib for psoriasis, but Bristol will be a new player in a category dominated by entrenched rivals.

Sanofi Bags EU Approvals But Fumes At Regulator

Although Nexviadyme has been approved, the French group is still unhappy about the EMA's view that the Pompe disease therapy should not be classified as a new active substance.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC144746

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel